Brokerage Firm Rating Update on GlaxoSmithKline PLC (GSK)

GlaxoSmithKline PLC (GSK) has an average broker rating of 2, which is interpreted as a Buy, as rated by 6 equity analysts. Nonetheless, 3 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 3 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

GlaxoSmithKline PLC (GSK) : The consensus price target for GlaxoSmithKline PLC (GSK) is $49.5 for the short term with a standard deviation of $0.71. The most optimist securities analyst among the 2 who monitor the stock believes that the stock can reach $50, however, the pessimist price target for the company is $49.


For the current week, the company shares have a recommendation consensus of Buy. Also, Argus Research maintains its view on GlaxoSmithKline PLC (NYSE:GSK) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Argus Research raises the price target from $48 per share to $50 per share on GlaxoSmithKline PLC. The rating by the firm was issued on August 12, 2016.

GlaxoSmithKline PLC (NYSE:GSK): stock was range-bound between the intraday low of $43.73 and the intraday high of $44.02 after having opened at $43.73 on Wednesdays session. The stock finally closed in the red at $43.73, a loss of -0.39%. The stock remained in the red for the whole trading day. The total traded volume was 3,080,958 shares. The stock failed to cross $44.02 in Wednesdays trading. The stocks closing price on Thursday was $43.99.

GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases. Its human immunodeficiency virus (HIV) business is managed through ViiV Healthcare. GSKs Vaccines has a portfolio of over 30 paediatric, adolescent, adult travel vaccines. GSKs Established Products Portfolio includes over 50 off-patent products, as well as its branded generics business and other local products. The Consumer Healthcare business develops and markets products in four categories, such as wellness, oral health, nutrition and skin health. Its brands include Sensodyne, Panadol, Horlicks, Polident, Paradontax, Tums, ENO, NiQuitin/Nicorette, Abreva, Zovirax and Aquafresh. It operates in the United Kingdom, the United States, Belgium and China.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.